Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could broccoli compound slow Parkinson's and MS? new trial launches

NCT ID NCT07360977

Disease control Sponsor: IRCCS Centro Neurolesi Bonino Pulejo Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is testing a supplement made from a broccoli compound (bioactivated GRA) in 300 people with Parkinson's disease, relapsing-remitting multiple sclerosis, or certain childhood nerve diseases. Participants will take the supplement daily for 6 months. Researchers will track changes in movement, thinking, brain scans, and quality of life to see if the compound can protect nerves and slow disease progression.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
bioactivated glucoraphanin (GRA) from broccoli
What this could lead to
If it works, this could point toward a simple dietary supplement that helps slow nerve damage and improve quality of life in Parkinson's, multiple sclerosis, and similar conditions.
What could go wrong
This is an early-stage trial with no placebo group, so results may be due to natural variation. The supplement is not a cure, and benefits may be small or absent.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 300 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jan 2026

An estimate. Start dates often move.

Expected to finish

May 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

1 year to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Inclusion Criteria for PD: * Male or female patients aged between 45-75 years old. * Clinical diagnosis of PD according to UK Brain Bank Criteria. * 3 months of clinical stability before study enrolment. * Anti-parkinsonian medication is fixed for at least 3 months prior to study entry. Inclusion Criteria for MS: * Male or female patients 18 years old or older. * Diagnosis of RR-MS according to McDonald criteria. * Expanded Disability Status Scale(EDSS) lower or equal to 5.5. * Stable disease for at least 30 days prior to study entry. * Stable disease-modifying therapy for at least 3 months prior to study entry. Common inclusion criteria for MS and PD: * No changes in drug treatment during 6 months-study treatment. * Patients understand and comply with the study procedure and are able to complete tests and examinations required by the project. * Written informed consent. Inclusion criteria for pediatric patients: * Eligible patients are those clinically stable; * Age range from 1 to 10, between 5 and 30 kg. * Patients not involved in other clinical trials. Exclusion Criteria: Exclusion criteria for PD and MS: * Absolute contraindications to Magnetic Resonance Imaging (MRI). * Concomitant neurological disease or severe co-morbidities able to influence outcomes such as spinal injury, cancer, dementia, or other central nervous system diseases such as stroke, epilepsy or psychiatric disorders; * Total score of Mini-Mental State Examination (MMSE)\<24. * Participating in other clinical trials. * Pregnant/lactating.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Multiple sclerosis (MS) - relapsing-remitting are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

multiple sclerosis Parkinson disease relapsing-remitting multiple sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Multiple sclerosis (MS) - relapsing-remitting Parkinson disease (disorder) Pediatric patients affected by neuromuscolar and degenerative diseases

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • IRCCS Centro Neurolesi Bonino Pulejo

    RECRUITING

    Messina, 98124, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.